• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia.罗芦必利酮单药治疗，一种用于精神分裂症阴性症状的治疗方法。
Int J Neuropsychopharmacol. 2025 Jun 6;28(6). doi: 10.1093/ijnp/pyaf032.
2
Mirtazapine adjunct for people with schizophrenia.米氮平辅助治疗精神分裂症患者。
Cochrane Database Syst Rev. 2018 May 26;5(5):CD011943. doi: 10.1002/14651858.CD011943.pub2.
3
Antipsychotic combinations for schizophrenia.用于精神分裂症的抗精神病药物联合治疗
Cochrane Database Syst Rev. 2017 Jun 28;6(6):CD009005. doi: 10.1002/14651858.CD009005.pub2.
4
Pimozide for schizophrenia or related psychoses.匹莫齐特用于治疗精神分裂症或相关精神病。
Cochrane Database Syst Rev. 2013 Nov 5;2013(11):CD001949. doi: 10.1002/14651858.CD001949.pub3.
5
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.氯氮平联合不同抗精神病药物治疗难治性精神分裂症。
Cochrane Database Syst Rev. 2017 Mar 23;3(3):CD006324. doi: 10.1002/14651858.CD006324.pub3.
6
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.氟哌啶醇与第一代抗精神病药物治疗精神分裂症及其他精神障碍的比较
Cochrane Database Syst Rev. 2015 Jan 16;1(1):CD009831. doi: 10.1002/14651858.CD009831.pub2.
7
Amisulpride for schizophrenia.用于治疗精神分裂症的氨磺必利
Cochrane Database Syst Rev. 2002;2002(2):CD001357. doi: 10.1002/14651858.CD001357.
8
Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.抗精神病药治疗伴有紧张症症状的精神分裂症谱系障碍。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD013100. doi: 10.1002/14651858.CD013100.pub2.
9
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
10
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.

本文引用的文献

1
Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities.精神分裂症当前新兴的治疗靶点与临床研究药物：挑战与机遇
Med Res Rev. 2025 Mar;45(2):755-787. doi: 10.1002/med.22086. Epub 2024 Sep 19.
2
Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence.针对精神分裂症症状的靶向治疗，或持续治疗以降低精神病复发风险。
Schizophr Bull. 2024 Jan 1;50(1):14-21. doi: 10.1093/schbul/sbad145.
3
Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments.精神分裂症的阴性症状：新出现的测量指标、途径和治疗方法。
Schizophr Res. 2023 Aug;258:71-77. doi: 10.1016/j.schres.2023.07.010. Epub 2023 Jul 28.
4
Long-term effects of Roluperidone on negative symptoms of schizophrenia.罗芦必利酮对精神分裂症阴性症状的长期影响。
Schizophr Res. 2023 May;255:9-13. doi: 10.1016/j.schres.2023.03.028. Epub 2023 Mar 16.
5
New Developments in the Treatment of Schizophrenia: An Expert Roundtable.治疗精神分裂症的新进展：专家圆桌会议。
Int J Neuropsychopharmacol. 2023 May 31;26(5):322-330. doi: 10.1093/ijnp/pyad011.
6
Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia.罗哌酮治疗精神分裂症阴性症状的疗效和安全性。
Schizophr Bull. 2022 May 7;48(3):609-619. doi: 10.1093/schbul/sbac013.
7
Structures of the σ receptor enable docking for bioactive ligand discovery.σ受体的结构有助于对接以发现生物活性配体。
Nature. 2021 Dec;600(7890):759-764. doi: 10.1038/s41586-021-04175-x. Epub 2021 Dec 8.
8
BDNF serum levels and cognitive improvement in drug-naive first episode patients with schizophrenia: A prospective 12-week longitudinal study.BDNF 血清水平与首发未用药精神分裂症患者认知改善的相关性：一项前瞻性 12 周纵向研究。
Psychoneuroendocrinology. 2020 Dec;122:104879. doi: 10.1016/j.psyneuen.2020.104879. Epub 2020 Sep 24.
9
Do DSM classifications help or hinder
drug development?
.DSM 分类法有助于还是阻碍了药物开发？
Dialogues Clin Neurosci. 2020 Mar;22(1):73-79. doi: 10.31887/DCNS.2020.22.1/mdavidson.
10
Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial.网络分析表明，动力缺乏是成功治疗阴性症状的最核心领域：来自罗匹尼罗随机临床试验的证据。
Schizophr Bull. 2020 Jul 8;46(4):964-970. doi: 10.1093/schbul/sbz141.

罗芦必利酮单药治疗，一种用于精神分裂症阴性症状的治疗方法。

Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia.

作者信息

Davidson Michael, Noel Nadine, Schmitt Florent, Luthringer Remy

机构信息

Minerva Neurosciences, 1500 District Avenue Burlington, MA 01803, USA.

Clinical and Basic Sciences Department Nicosia University Medical School, Nicholas St 93, Egkomi Lefkosias 2408, Cyprus.

出版信息

Int J Neuropsychopharmacol. 2025 Jun 6;28(6). doi: 10.1093/ijnp/pyaf032.

DOI:10.1093/ijnp/pyaf032
PMID:40392301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12202136/
Abstract

Roluperidone is a drug in development targeting primary negative symptoms in schizophrenia, which binds sigma-2, 5-HT2A, and alpha1a receptors. Roluperidone administered as monotherapy to patients suffering from mild to moderate negative symptoms and withdrawal from antipsychotic drugs, improved negative symptoms in 2 clinical trials. The patients who were symptomatically stable for 3 or 6 months before antipsychotic drug withdrawal showed a very low rate of psychotic symptoms worsening over 6 or 9-month trial duration. Focus: Treatment of primary negative symptoms in a subgroup of patients suffering from schizophrenia.

摘要

罗芦必利酮是一种正在研发的用于治疗精神分裂症原发性阴性症状的药物，它可与σ-2、5-HT2A和α1a受体结合。在两项临床试验中，将罗芦必利酮作为单一疗法给予患有轻至中度阴性症状且正在停用抗精神病药物的患者，改善了阴性症状。在停用抗精神病药物前症状稳定3或6个月的患者，在6或9个月的试验期内精神病症状恶化率非常低。重点：治疗精神分裂症亚组患者的原发性阴性症状。